READ-OUT / COMMON QUESTIONS
PT-141: common questions, answered from the record
Twenty-two direct answers, cited where they make a quantitative claim. Findings only — this digest recommends no dose.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors. It is FDA-approved (2019) for one use only: acquired, generalized HSDD in premenopausal women [6]. Every other use is off-label.
What is PT-141 peptide?
A melanocortin receptor agonist peptide — a synthetic cyclic heptapeptide lactam analogue of alpha-MSH, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is the same molecule as the approved drug bremelanotide, with a molecular weight of 1025.2 Da [1].
What does the PT-141 peptide do?
It activates central melanocortin receptors (chiefly MC4R) in hypothalamic and limbic circuits tied to sexual desire and arousal [1]. In the approved population it improved sexual desire and reduced desire-related distress versus placebo by a statistically significant but modest margin [3].
What is PT-141 used for?
Its only FDA-approved use is acquired, generalized HSDD in premenopausal women [6]. Use in men, for erectile dysfunction, in postmenopausal women, or for sexual performance is off-label and, in the male/erectile setting, supported only by early-phase, investigational evidence [1].
Is PT-141 the same as bremelanotide?
Yes. Bremelanotide is the international nonproprietary name (INN) for PT-141; 'PT-141' is the development designation for the same melanocortin receptor agonist. They are one molecule under two names.
What is bremelanotide?
Bremelanotide is the approved melanocortin (MC3R/MC4R) receptor agonist that researchers call PT-141 — an injectable peptide FDA-approved in 2019 for acquired, generalized HSDD in premenopausal women [6].
How does PT-141 work?
It works centrally. By activating MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopaminergic pathways governing sexual motivation, rather than acting peripherally on vascular blood flow [1].
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with secondary MC3R agonism, both concentrated in the central nervous system [1]. Peripheral MC1R activation underlies the hyperpigmentation seen with repeated dosing [6].
Does PT-141 work through the brain or through blood flow?
Through the brain. Unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle to improve blood flow, PT-141 acts on the central circuitry of sexual motivation; an fMRI study found MC4R agonism altered brain processing of erotic stimuli [5].
What is a melanocortin receptor agonist?
A compound that activates melanocortin receptors — a family of five G-protein-coupled receptors (MC1R-MC5R) that respond to peptides such as alpha-MSH. PT-141 targets the central MC3R/MC4R subtypes linked to sexual desire and appetite [1].
Does PT-141 increase testosterone?
No. PT-141 does not act via the hypothalamic-pituitary-gonadal (HPG) axis and does not directly raise testosterone. It is a central melanocortin agonist — not a hormone-axis stimulant and not a PDE-5 inhibitor [1].
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors (such as sildenafil and tadalafil) act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on melanocortin circuits governing sexual desire and arousal [1]. They have fundamentally different mechanisms and approved uses.
What is the PT-141 dosage?
Reported only as a label/trial finding, not advice: the approved label specifies 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 h and no more than 8 per month [6]. Phase 2 dose-finding used 0.75, 1.25, and 1.75 mg [3].
How much PT-141 should I take?
This digest reports no dose for any individual. The only approved dose, for HSDD in premenopausal women, is 1.75 mg subcutaneous as-needed (max 1/24 h, 8/month) [6]. Any other use is off-label and outside the approval.
How much PT-141 to inject?
The approved injectable dose described in the label is 1.75 mg subcutaneous as-needed for the HSDD indication [6]. This is reported as a regulatory finding, not a protocol to follow; material sold as 'research chemical' is for laboratory use only.
What is the PT-141 dosage for women?
For the approved indication (acquired, generalized HSDD in premenopausal women), the label dose is 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, with the 1-per-24-h and 8-per-month limits [6]. Reported as a finding, not advice.
How often can you take PT-141?
Reported only as the approved label limit, not as advice: the US prescribing information specifies no more than one 1.75 mg subcutaneous dose per 24 hours and no more than 8 doses per month for the approved HSDD indication in premenopausal women [6].
What are the side effects of PT-141?
In the trials and label, the most common drug-related adverse events were nausea (~40% over long-term use, and the leading reason for discontinuation), flushing (~21%), and headache (~12%), plus injection-site reactions and nasal congestion [4]. A transient blood-pressure rise with a heart-rate drop is documented, and hyperpigmentation occurs with repeated dosing [6].
Why does PT-141 cause nausea?
Nausea is the most frequent treatment-emergent adverse event (40.4% in the 52-week extension) and a notable driver of discontinuation [4]. It is consistent with central melanocortin (MC4R) signaling — the same pathway as the intended effect. Injection timing and dose strategy have been studied as mitigations [8].
Does PT-141 raise blood pressure?
Yes, transiently. Ambulatory blood-pressure monitoring documented a temporary rise in blood pressure with a fall in heart rate after dosing [13]. The label warns against use in uncontrolled hypertension or known cardiovascular disease [6].
Does PT-141 cause skin darkening or hyperpigmentation?
Hyperpigmentation of the face, gums, and breasts is reported with repeated frequent dosing and is attributed to MC1R activation, which increases melanin [6]. It is a documented consideration with the melanocortin-agonist class, and it is dose-frequency-dependent.
Is PT-141 safe?
In the approved HSDD population, the 52-week extension showed no new safety signals, but tolerability is limited mainly by nausea [4]. Cardiovascular precautions (a transient blood-pressure rise; contraindicated in uncontrolled hypertension or cardiovascular disease) and hyperpigmentation with repeated dosing apply [6]. Off-label use is not supported by the approval, and 'research chemical' material has no regulatory oversight of identity or purity.